The transformation of HIV therapy: One pill once a day

Choudhary, Madhu C.; Mellors, John W.

doi:10.1177/13596535211062396

Cited by 11 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6] In most cases, singletablet regimens are prescribed because they reduce regimen complexity, improve adherence, and maintain viral load (VL) suppression (ie, noninferior to comparator arms). 7 Different combinations of ARV drugs are available for the treatment of HIV infections. 4,5,[8][9][10][11][12][13][14] BIC/FTC/TAF is one of newest single-tablet regimens available and is recommended for initial therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain

et al. 2023

View full text Add to dashboard Cite

Background: The evaluation of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in clinical trials has shown high rates of virological suppression but information about its use in real-life settings is scarce. Objective: To evaluate the effectiveness, safety, durability, and predictive variables of therapeutic failure of BIC/FTC/TAF in a real-life cohort. Methods This observational, retrospective, multicentered cohort study included treatment-naive (TN) and treatment-experienced (TE) adult patients living with HIV (PLWH) who started treatment with BIC/FTC/TAF from January 1, 2019, to January 31, 2022. Treatment effectiveness (based on intention-to-treat [ITT], modified ITT [mITT], and on-treatment [OT]), tolerability, and safety were evaluated in all patients who started BIC/FTC/TAF antiretroviral therapy. Results: We included a total of 505 PLWH of whom 79 (16.6%) were TN and 426 (83.4%) were TE. Patients were followed up for a median (interquartile range [IQR]) of 19.6 (9.6-27.3) months, and 76% and 56% of PLWH reached month 6 and month 12 of treatment, respectively. Rates of TN PLWH with HIV-RNA <50 copies/mL in the OT, mITT, and ITT groups were 94%, 80%, and 62%, respectively, after 12 months of BIC/FTC/TAF treatment. Rates of TE PLWH with HIV-RNA <50 copies/mL were 91%, 88%, and 75% at month 12. The multivariate analysis revealed that neither age, sex, CD4 cell count <200 cells/μL, or viral load >100 000 copies/mL were associated with therapeutic failure. Conclusion and relevance: Our real-life data showed that BIC/FTC/TAF is effective and safe for use in the treatment of both TN and TE patients in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

“…4-6 In most cases, single-tablet regimens are prescribed because they reduce regimen complexity, improve adherence, and maintain viral load (VL) suppression (ie, noninferior to comparator arms). 7…”

Section: Introductionmentioning

confidence: 99%

Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This lack of efficacy may contribute to explain why studies that investigated HIV were conducted in a well-defined period and stopped after 2006. Not to mention the introduction of the first triple combination of antiretroviral drugs in a single tablet, a fundamental step toward an effective and generally well-tolerated option for the management of HIV infection [ 67 ], that may have caused an interest loss in searching for supplemental treatments for this disease.…”

Section: Discussionmentioning

confidence: 99%

What Are the Effects of Vitamin A Oral Supplementation in the Prevention and Management of Viral Infections? A Systematic Review of Randomized Clinical Trials

et al. 2022

View full text Add to dashboard Cite

Vitamin A (VA) deficiency is associated with increased host susceptibility to infections, but evidence on its role in the prevention and management of viral infections is still lacking. This review aimed at summarizing the effects of VA supplementation against viral infections to support clinicians in evaluating supplemental treatments. PubMed, Scopus, and Web of Science were searched. Randomized clinical trials comparing the direct effects of VA oral supplementation in any form vs. placebo or standard of care in the prevention and/or management of confirmed viral infections in people of any age were included. A narrative synthesis of the results was performed. The revised Cochrane Risk-Of-Bias tool was used to assess quality. Overall, 40 articles of heterogeneous quality were included. We found data on infections sustained by Retroviridae (n = 17), Caliciviradae (n = 2), Flaviviridae (n = 1), Papillomaviridae (n = 3), Pneumoviridae (n = 4), and Paramyxoviridae (n = 13). Studies were published between 1987 and 2017 and mostly conducted in Africa. The findings were heterogeneous across and within viral families regarding virological, immunological, and biological response, and no meaningful results were found in the prevention of viral infections. For a few diseases, VA-supplemented individuals had a better prognosis and improved outcomes, including clearance of HPV lesions or reduction in some measles-related complications. The effects of VA oral supplementation seem encouraging in relation to the management of a few viral infections. Difference in populations considered, variety in recruitment and treatment protocols might explain the heterogeneity of the results. Further investigations are needed to better identify the benefits of VA administration.

show abstract

“…Previous studies have revealed the efforts to design antiretroviral regimens that are still effective and relatively safe from drug side effects. One of these approaches is the simplification of the multi-tablet regimen to a single tablet regimen that people living with HIV only take one dose of a single tablet per day [16,17]. Another study stated there was a significant relationship between the use of a single tablet regimen and a high level of adherence to antiretroviral therapy [18,19].…”

Section: Introductionmentioning

confidence: 99%

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Adiningsih¹,

Widiyanti²,

Rokhmad³

2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

Tenofovir lamivudine efavirenz (TLE) as a single-tablet regimen is preferred to the long use of combination antiretroviral therapy. TLE is safer than another antiretroviral drug regimen for first-line of Human immunodeficiency virus (HIV) treatment. However, there is little information about the side effects of TLE during first-time therapy among people living with HIV in Jayapura. This study aimed to assess the TLE side effect and its efficacy among people living with HIV in Jayapura, Papua. This was a cross-sectional study involving 77 people living with HIV who took a single-tablet regimen of TLE for one to two years of antiretroviral therapy, comply the inclusion criteria, and provided consent to participate. Data collection was conducted through CD4 + tests, medical records, and interviews at Jayapura City Hospital. Descriptive statistics were used to determine the proportion of relevant variables. The results described that most groups of people living with HIV were adult group (93.5%), female (61.0%), Papuan (64.9%), had WHO clinical stage III-IV (67.5%), had CD4 + counts < 350 cell/µL in the early therapy (79.2%) and CD4 + counts ≥ 350 cell/µL at the time of the study (57.1%), and experienced TLE side effect (71.4%). The most symptoms of TLE side effects among people living with HIV were headache (61.8%), nausea (34.5%), and nightmare (29.1%). As many as 70.9% of people living with HIV experienced these symptoms for less than 2 weeks. TLE was still effective, indicated by an increase of CD4 + cell count average from 242.6 cell/mm 3 at the early therapy to 436.6 cell/mm 3 during this study, with good adherence to drug therapy (>95% adherence) by 53.2% of people living with HIV. The side effects of TLE can still be tolerated by most people living with HIV so the therapy can be continued without altering the regimen.

show abstract

The transformation of HIV therapy: One pill once a day

Cited by 11 publications

References 41 publications

Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain

Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain

What Are the Effects of Vitamin A Oral Supplementation in the Prevention and Management of Viral Infections? A Systematic Review of Randomized Clinical Trials

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Contact Info

Product

Resources

About